Wave Life Sciences Ltd. (NASDAQ:WVE – Get Free Report) major shareholder Plc Gsk acquired 2,791,930 shares of the firm’s stock in a transaction on Friday, September 27th. The stock was purchased at an average price of $8.00 per share, with a total value of $22,335,440.00. Following the purchase, the insider now owns 16,775,691 shares in the company, valued at approximately $134,205,528. The purchase was disclosed in a filing with the SEC, which is accessible through the SEC website. Major shareholders that own at least 10% of a company’s stock are required to disclose their sales and purchases with the SEC.
Wave Life Sciences Trading Up 1.2 %
WVE traded up $0.10 during trading on Tuesday, hitting $8.30. 1,152,767 shares of the company traded hands, compared to its average volume of 988,589. Wave Life Sciences Ltd. has a 1 year low of $3.50 and a 1 year high of $9.92. The stock’s 50-day simple moving average is $6.07 and its two-hundred day simple moving average is $5.85. The company has a market cap of $1.02 billion, a PE ratio of -15.81 and a beta of -1.13.
Wave Life Sciences (NASDAQ:WVE – Get Free Report) last released its quarterly earnings results on Thursday, August 8th. The company reported ($0.25) earnings per share for the quarter, missing the consensus estimate of ($0.16) by ($0.09). The company had revenue of $19.69 million for the quarter, compared to analysts’ expectations of $24.80 million. Wave Life Sciences had a negative net margin of 66.50% and a negative return on equity of 1,395.99%. During the same quarter in the previous year, the company posted ($0.20) EPS. Equities analysts expect that Wave Life Sciences Ltd. will post -1.04 EPS for the current year.
Institutional Trading of Wave Life Sciences
Wall Street Analysts Forecast Growth
Several equities research analysts have commented on the stock. Mizuho reaffirmed an “outperform” rating and set a $19.00 price objective on shares of Wave Life Sciences in a report on Tuesday, June 25th. HC Wainwright upped their target price on Wave Life Sciences from $15.00 to $22.00 and gave the stock a “buy” rating in a research note on Wednesday, September 25th. JPMorgan Chase & Co. initiated coverage on shares of Wave Life Sciences in a report on Friday. They set an “overweight” rating and a $13.00 price objective for the company. Finally, B. Riley started coverage on shares of Wave Life Sciences in a report on Thursday, September 19th. They issued a “buy” rating and a $11.00 price objective for the company. Two investment analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $13.75.
Check Out Our Latest Stock Report on Wave Life Sciences
About Wave Life Sciences
Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders.
Featured Articles
- Five stocks we like better than Wave Life Sciences
- Buy P&G Now, Before It Sets A New All-Time High
- Why Lennar Stock Could Be the Best Play in the Housing Market
- Insider Trading – What You Need to Know
- 2 Energy Stocks Fueling the AI Datacenter Boom
- Financial Services Stocks Investing
- Will Marinus Pharmaceuticals Be the Next Big Winner in Biotech?
Receive News & Ratings for Wave Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Wave Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.